Crossmark

Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer's Disease

Crossref DOI link: https://doi.org/10.14283/jpad.2023.123

Published Print: 2023-11

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Cohen, Sharon

van Dyck, C.H.

Gee, M.

Doherty, T.

Kanekiyo, M.

Dhadda, S.

Li, D.

Hersch, S.

Irizarry, M.

Kramer, L.D.
License Information

Text and Data Mining valid from 2023-11-01

Text and Data Mining valid from 2023-11-01

Version of Record valid from 2023-09-29
More Information

This article is maintained by: Elsevier

Article Title: Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer's Disease

Journal Title: The Journal of Prevention of Alzheimer's Disease

CrossRef DOI link to publisher maintained version: https://doi.org/10.14283/jpad.2023.123

Content Type: article

Copyright: Copyright © 2023 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS